Boutique adviser’s work for two former executives has threatened its lucrative ties to the vaccine maker
Not quickly, anyway
Plus, the senior bankers at the centre of HSBC’s plans to cut costs and 7-Eleven’s latest tactic to fend of a $47bn hostile takeover
A seemingly misfired message has embroiled Albert Bourla and his company in a high-stakes activist battle
Hedge fund had enlisted help from ex-chair Ian Read and former finance chief Frank D’Amelio
Fund run by Jeff Smith builds $1bn stake in vaccine maker and pitches shake-up plan
The drugmaker is worth less now than before the pandemic
Plus, Jane Street comes for Goldman’s trading crown and Byju’s can’t find the money
Ian Read has called his successors about the activist’s ideas for turning round the vaccine maker
Pharma giant’s share price has fallen below pre-pandemic levels after shortlived bump from Covid vaccine
Company’s chief oncology officer says reforms risk discouraging treatments for paediatric and rare conditions
Jab makers fall behind Moderna in post-pandemic market with disappointing results
Pharma groups could see almost threefold drop in demand due to US health official decision, says Airfinity
Pharma group seeks to catch up with rivals Eli Lilly and Novo Nordisk in sector projected to be worth $130bn a year
Pfizer and BioNTech infringed pharmaceutical group’s mRNA patent, High Court in London rules
Decision is a boon for the mRNA-vaccine maker in its legal fight to recoup pandemic profits from rivals
Agreement aims to resolve a big portion of litigation in Delaware over discontinued heartburn drug
Drugmaker follows Eli Lilly in cutting out middlemen and selling directly to patients
US pharma group follows Eli Lilly with website for patients to obtain medication online
Moderna alleges Pfizer and BioNTech infringed its patents in use of mRNA platform
People who progress with little regard for colleagues are likely to hit a ceiling
Millions of Paxlovid pills have gone unused as tight controls restrict access
Company would have been better off following Roche’s route to market for anti-obesity treatment
US drugmaker is trying to chart its future without blockbuster Covid-19 products
Case studies in best practice among general counsel and company legal teams in North America
